Atirmociclib & Fulvestrant Significantly Improve Progression-Free Survival in [Cancer Type]
(Replace "[Cancer Type]" with the specific cancer the article discusses – e.g., "Breast Cancer", "HR+/HER2- Breast Cancer")
Alternative, if space is limited:
Atirmociclib + Fulvestrant: Improved Survival in [Cancer Type]
Berlin, Germany – In a significant development for patients battling advanced hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, new data reveals that treatment combining atirmociclib with fulvestrant demonstrates a statistically and clinically meaningful improvement in progression-free survival (PFS). The findings, stemming from the Phase 2 FOURLIGHT-1 study, offer a potential new option for individuals whose disease … Read more